Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > LUM-201

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 15, 2023 9:43am

73 Views

Post# 35786456

RE: LUM-201

fossi_2002 wrote:
Always working with half-truths and ignoring the competition, that is the method of Proph.

GHRYVELIN (previously Macimorelin Aeterna Zentaris) will soon be facing competition from Lumos Pharma with its product LUM 201.
A study by Globaldata quotes the following:
The launch of LUM-201 has the potential to increase treatment rates and treatment adherence among PEM-positive pediatric patients due to the more favorable oral administration route.

https://www.globaldata.com/store/report/growth-hormone-secretagogue-receptor-type-1-drugs-in-development-analysis/

https://www.fiercebiotech.com/biotech/lumos-stock-rockets-phase-2-results-bring-first-oral-growth-hormone-drug-one-step-closer

I've been posting about a AEZS's diagnostic test for growth hormone deficiency and you post about a therapy for growth hormone deficiency? And you post the therapy(LUM-201) could increase treatment rates for growth hormone deficiency? How will people know they need to be treated for growth hormone deficiency? With AEZS's growth hormone deficiency test? Seems like better treatments for growth hormone deficiency could lead to increased awareness and diagnosis of growth hormone deficiency using AEZS's test.

Bing, "LUM-201 is an investigational, once-daily, orally administered small molecule that promotes the secretion of Growth Hormone (GH) from the pituitary gland 1. It has been observed to increase the amplitude of endogenous pulsatile GH secretion, which mimics the natural pattern of GH secretion via potent agonism of the growth hormone secretagogue receptor 1. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU 2.

According to Lumos Pharma’s press release, topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all primary and secondary endpoints 2. The data from the OraGrowtH210 Trial demonstrated annualized height velocity (AHV) on the 1.6 mg/kg dose of orally administered LUM-201 of 8.2 cm/yr at six months and 8.0 cm/yr at 12 months on treatment, in line with historical data in moderate pediatric growth hormone deficiency (PGHD) patients and within the targeted 2 cm/yr margin of the comparator injectable recombinant growth hormone (rhGH) arm 2. Lumos Pharma expects to finalize its plans for a phase 3 pivotal trial with the FDA in its end of phase 2 meeting anticipated in the first half of 2024 3."